Human P2Y₆ Receptor:  Molecular Modeling Leads to the Rational Design of a Novel Agonist Based on a Unique Conformational Preference

Human P2Y₆ Receptor:  Molecular Modeling Leads to the Rational Design of a Novel Agonist Based on a Unique Conformational Preference Pyrimidine Ribonucleotides with Enhanced Selectivity as P2Y₆ Receptor Agonists: Novel 4-Alkyloxyimino, (S)-Methanocarba, and 5′-Triphosphate γ-Ester Modifications 5-OMe-UDP is a Potent and Selective P2Y₆-Receptor Agonist Structure−Activity Relationships of Uridine 5‘-Diphosphate Analogues at the Human P2Y₆Receptor Molecular Modeling of the Human P2Y₂ Receptor and Design of a Selective Agonist, 2‘-Amino-2‘-deoxy-2-thiouridine 5‘-Triphosphate Methanocarba Modification of Uracil and Adenine Nucleotides:  High Potency of Northern Ring Conformation at P2Y₁, P2Y₂, P2Y₄, and P2Y₁₁ but Not P2Y₆ Receptors Adenine Nucleotide Analogues Locked in a Northern Methanocarba Conformation:  Enhanced Stability and Potency as P2Y₁ Receptor Agonists Molecular dynamics simulation of the P2Y14 receptor. Ligand docking and identification of a putative binding site of the distal hexose moiety Synthesis and potency of novel uracil nucleotides and derivatives as P2Y2 and P2Y6 receptor agonists UDP made a highly promising stable, potent, and selective P2Y6-receptor agonist upon introduction of a boranophosphate moiety